MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Viking Therapeutics Inc

Open

BrancheGesundheitswesen

25.18 -2.02

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

24.3

Max

25.87

Schlüsselkennzahlen

By Trading Economics

Einkommen

-10M

-35M

EPS

-0.32

Angestellte

36

EBITDA

-9.6M

-46M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+248.66% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

23. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-570M

2.7B

Vorheriger Eröffnungskurs

27.2

Vorheriger Schlusskurs

25.18

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

Viking Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Apr. 2025, 14:14 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Viking Seen as Potential Ticket To Get Pfizer Back Into Obesity Game -- Market Talk

7. Feb. 2025, 10:30 UTC

Top News

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

23. Dez. 2024, 15:04 UTC

Top News

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13. Dez. 2024, 14:53 UTC

Top News

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

4. Nov. 2024, 12:22 UTC

Top News

Viking Therapeutics Jumps On Latest Obesity Drug Data -- IBD

4. Nov. 2024, 12:00 UTC

Top News

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

4. Nov. 2024, 10:11 UTC

Heiße Aktien

Stock to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel -- WSJ

4. Okt. 2024, 12:01 UTC

Top News

As Weight-Loss Drugs Battle, Upstart Viking -2-

4. Okt. 2024, 12:01 UTC

Top News

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

20. Sept. 2024, 13:55 UTC

Top News

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

25. Juli 2024, 15:03 UTC

Ergebnisse

Viking Stock Jumps After Company Speeds Development Its Weight-Loss Pill -- Barrons.com

Peer-Vergleich

Kursveränderung

Viking Therapeutics Inc Prognose

Kursziel

By TipRanks

248.66% Vorteil

12-Monats-Prognose

Durchschnitt 89.92 USD  248.66%

Hoch 125 USD

Tief 30 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Viking Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

17 ratings

15

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

25.48 / 25.7Unterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Weak Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.